source
- ADARx prices $446.3 million Nasdaq debut, boosting biotech IPO waveADARx Pharmaceuticals, a RNA interference focused biotech, announced pricing of its initial public offering at $446.3 million on Nasdaq. The offering was upsized, reflecting strong investor demand…
- Pharma groups urge FDA to clarify criteria for approving drugs based on a single pivotal trialPharmaceutical companies and industry associations are asking the U.S. Food and Drug Administration for more detailed guidance on when a single pivotal clinical trial, supported by additional confi…